| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10633-007-9108-3 |
| P698 | PubMed publication ID | 18188629 |
| P2093 | author name string | Monica Lövestam-Adrian | |
| Sten Andréasson | |||
| Vesna Ponjavic | |||
| Ulrika Kjellström | |||
| P2860 | cites work | Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin | Q74696609 |
| Reversibility of vigabratin-induced visual-field defect | Q78180630 | ||
| Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings | Q28377661 | ||
| Characteristics of a unique visual field defect attributed to vigabatrin | Q28378109 | ||
| Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer | Q33234962 | ||
| Characterization of vigabatrin‐associated optic atrophy | Q33972736 | ||
| Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children | Q33982061 | ||
| Effects of vigabatrin on evoked potentials in epileptic patients | Q34396870 | ||
| Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients | Q34396879 | ||
| The legacy of vigabatrin in a regional epilepsy clinic | Q34788174 | ||
| Visual field defects associated with vigabatrin therapy | Q35454439 | ||
| A controlled study comparing visual function in patients treated with vigabatrin and tiagabine | Q35472173 | ||
| Severe persistent visual field constriction associated with vigabatrin | Q36242274 | ||
| Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats | Q38978862 | ||
| Changes in the electroretinogram resulting from discontinuation of vigabatrin in children | Q41849881 | ||
| Second study supports results of Whitehall study after retirement | Q42783068 | ||
| Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. | Q42783865 | ||
| Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions | Q42783891 | ||
| Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies | Q42783917 | ||
| Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. | Q42783920 | ||
| Visual function loss from vigabatrin: effect of stopping the drug | Q43505004 | ||
| Vigabatrin effect on inner retinal function | Q43686221 | ||
| Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication | Q43689374 | ||
| No reversion in vigabatrin-associated visual field defects | Q43809209 | ||
| Visual field constriction and electrophysiological changes associated with vigabatrin. | Q43985706 | ||
| Visual field and electrophysiological abnormalities due to vigabatrin | Q43985711 | ||
| Electro-ophthalmological recovery after withdrawal from vigabatrin | Q43985714 | ||
| The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms | Q43985718 | ||
| Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal | Q44113272 | ||
| Is visual field constriction in epilepsy patients treated with vigabatrin reversible? | Q44114070 | ||
| Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal | Q44358411 | ||
| Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina | Q44489274 | ||
| Vigabatrin: longterm follow-up of electrophysiology and visual field examinations | Q44596992 | ||
| Peripheral retinal dysfunction in patients taking vigabatrin | Q44705205 | ||
| Standard for clinical electroretinography (2004 update). | Q45084219 | ||
| Vigabatrin toxicity in children | Q46579485 | ||
| Symptomatic and asymptomatic visual loss in patients taking vigabatrin. | Q50516870 | ||
| Evoked potential monitoring of vigabatrin patients | Q67231557 | ||
| Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects | Q73016916 | ||
| No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicenter Group | Q73155695 | ||
| Recovery of visual field constriction following discontinuation of vigabatrin | Q73954236 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 93-101 | |
| P577 | publication date | 2008-01-10 | |
| P1433 | published in | Documenta Ophthalmologica | Q15766028 |
| P1476 | title | Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy | |
| P478 | volume | 117 |
| Q45187625 | Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication |
| Q46027023 | Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye. |
| Q39435601 | Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures |
| Q83078744 | The safety and tolerability of newer antiepileptic drugs in children and adolescents |
| Q89696134 | Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice |
Search more.